By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > MAO inhibitor > Isocarboxazid

Isocarboxazid

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|638 words

Isocarboxazid: Drug Profile and Safety Information

What is Isocarboxazid?

Isocarboxazid is a prescription antidepressant medication that belongs to a class of drugs called monoamine oxidase inhibitors (MAOIs). It is primarily used to treat major depressive disorder, particularly in patients who have not responded adequately to other types of antidepressants. Due to its potential for serious drug and food interactions, isocarboxazid is typically reserved for cases where other treatment options have proven ineffective.

Uses

  • Major depressive disorder: The primary indication for isocarboxazid is treating depression that has not responded to other antidepressants such as SSRIs or tricyclics.
  • Atypical depression: May be particularly effective for depression characterized by mood reactivity, increased appetite, excessive sleep, and rejection sensitivity.
  • Treatment-resistant depression: Used when patients have failed to respond to multiple other antidepressant medications.
  • Panic disorder: Sometimes prescribed off-label for panic disorder when other treatments have been unsuccessful.
  • Social anxiety disorder: May be used in severe cases that have not responded to first-line treatments.

How it works

Isocarboxazid works by blocking the enzyme monoamine oxidase, which is responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. By preventing the breakdown of these mood-regulating chemicals, isocarboxazid increases their availability in the synapses between nerve cells. This enhanced neurotransmitter activity is believed to improve mood and reduce symptoms of depression.

Side effects

Common side effects:

  • Dizziness and lightheadedness
  • Drowsiness or fatigue
  • Dry mouth
  • Constipation
  • Blurred vision
  • Weight gain
  • Sleep disturbances
  • Sexual dysfunction

Serious side effects requiring immediate medical attention:

Submit Your Paper
GMJ_Submit_Banner
  • Severe headache, which may indicate a hypertensive crisis
  • Rapid or irregular heartbeat
  • Chest pain or difficulty breathing
  • Sudden severe nausea and vomiting
  • Signs of liver problems such as yellowing of skin or eyes

Warnings and precautions

  • Dietary restrictions: Patients must follow a strict tyramine-free diet, avoiding aged cheeses, cured meats, fermented foods, and certain alcoholic beverages to prevent dangerous blood pressure spikes.
  • Suicide risk: Like all antidepressants, isocarboxazid may increase suicidal thoughts in young adults under 25, especially during the first few weeks of treatment.
  • Cardiovascular conditions: Should be used with extreme caution in patients with heart disease, high blood pressure, or history of stroke due to risk of hypertensive crisis.
  • Pregnancy and breastfeeding: Should only be used during pregnancy if potential benefits outweigh risks; not recommended during breastfeeding due to unknown effects on infants.
  • Liver and kidney function: Requires careful monitoring in patients with impaired liver or kidney function, as drug clearance may be affected.

Interactions

  • Other antidepressants (SSRIs, SNRIs, tricyclics): Can cause potentially fatal serotonin syndrome; requires washout period between medications.
  • Stimulants and decongestants: May cause dangerous blood pressure elevation when combined with medications containing pseudoephedrine or phenylephrine.
  • Pain medications (meperidine, tramadol): Risk of serotonin syndrome and other serious reactions.
  • Blood pressure medications: May enhance hypotensive effects or interfere with blood pressure control.
  • Tyramine-containing foods: Can trigger hypertensive crisis when consumed with aged cheeses, wine, cured meats, and fermented products.
  • St. John’s Wort: Herbal supplement that increases risk of serotonin syndrome.
  • Ginseng and ephedra: May increase blood pressure to dangerous levels.
  • Anesthetics: May interact with anesthesia; inform all healthcare providers about isocarboxazid use before any surgical procedures.

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose for adults is 10 mg taken twice daily, which may be gradually increased to a maximum of 60 mg per day divided into 2-4 doses. Most patients respond to doses between 20-40 mg daily. Dosage adjustments should be made slowly, typically at intervals of 2-4 weeks, to allow for full therapeutic effect and minimize side effects. All dosage decisions must be individualized and determined by a qualified healthcare provider based on patient response, tolerability, and medical history.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Isocarboxazid." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/isocarboxazid/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Why Spinach Iron Doesn’t Count Like Meat Iron: The Bioavailability Gap

A cup of spinach contains 6 mg of iron but only 2–20%…

How Coffee Brewing Method Affects Cholesterol: The Science Behind Diterpenes and Filters

Coffee's effect on cholesterol depends entirely on brewing method. Unfiltered coffee—French press,…

Muscle rebuilds in three months, but bone takes twice as long—and protein supplements don’t speed it up

Muscle tissue rebuilds completely every three months, while bone takes up to…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Tranylcypromine

By
Prof. Giorgi Pkhakadze
02/06/2026

Phenelzine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up